Skip to main content

Table 1 Overview over the transition probabilities

From: Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine

Ā 

To ... (M: Mezavant cohort; A: Asacol cohort)

From ...

1st line

1st line increased dosage

2nd line

Failure/relapse

Surgery

Post surgery

Remission

Death

Active UC: 1st line

Ā 

M: 59.5%

A: 67.4%

Ā Ā Ā Ā 

M: 40.5%

A: 32.6%

0.0%**

Active UC: 1st line increased dosage

Ā Ā 

M: 38.5%

A: 39.0%

Ā Ā Ā 

M: 61.5%

A: 60.0%

0.0%**

Active UC: 2nd line

Ā Ā Ā 

M: 32.0%

A: 32.0%

Ā Ā 

M: 68.0%

A: 68.0%

0.0%**

Active UC: Failure/relapse

Ā Ā Ā Ā 

M: 25.8%

A: 25.8%

Ā 

M: 74.2%

A: 74.2%

0.0%**

Surgery

Ā Ā Ā Ā Ā 

M: 97.9%

A: 97.9%

Ā 

M: 2.1%

A: 2.1%

Post surgery

Ā Ā Ā Ā Ā 

M: 100.0%

A: 100.0%

Ā 

0.0%**

Remission

M: 6.5%*

A: 9.2%*

Ā Ā Ā Ā Ā 

M: 93.5%

A: 90.8%

0.0%**

Death

Ā Ā Ā Ā Ā Ā Ā 

M: 100.0%

A: 100.0%

  1. * This figure decreases as time spent in remission decreases the risk of active episodes [14, 15]
  2. ** The overall cause mortality data [16] (dependent on the age cohort) is below 0.05% and is therefore displayed in the table as 0.0%.